7JVP image
Entry Detail
PDB ID:
7JVP
EMDB ID:
Title:
Cryo-EM structure of SKF-83959-bound dopamine receptor 1 in complex with Gs protein
Biological Source:
Host Organism:
PDB Version:
Deposition Date:
2020-08-22
Release Date:
2021-02-24
Method Details:
Experimental Method:
Resolution:
2.90 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Guanine nucleotide-binding protein G(s) subunit alpha isoforms short
Chain IDs:B (auth: A)
Chain Length:393
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1
Chain IDs:C (auth: B)
Chain Length:354
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2
Chain IDs:D (auth: G)
Chain Length:67
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:nanobody 35
Chain IDs:E (auth: N)
Chain Length:135
Number of Molecules:1
Biological Source:synthetic construct
Polymer Type:polypeptide(L)
Description:D(1A) dopamine receptor
Chain IDs:A (auth: R)
Chain Length:502
Number of Molecules:1
Biological Source:Homo sapiens
Primary Citation
Structural insights into the human D1 and D2 dopamine receptor signaling complexes.
Cell 184 931 942.e18 (2021)
PMID: 33571431 DOI: 10.1016/j.cell.2021.01.027

Abstact

The D1- and D2-dopamine receptors (D1R and D2R), which signal through Gs and Gi, respectively, represent the principal stimulatory and inhibitory dopamine receptors in the central nervous system. D1R and D2R also represent the main therapeutic targets for Parkinson's disease, schizophrenia, and many other neuropsychiatric disorders, and insight into their signaling is essential for understanding both therapeutic and side effects of dopaminergic drugs. Here, we report four cryoelectron microscopy (cryo-EM) structures of D1R-Gs and D2R-Gi signaling complexes with selective and non-selective dopamine agonists, including two currently used anti-Parkinson's disease drugs, apomorphine and bromocriptine. These structures, together with mutagenesis studies, reveal the conserved binding mode of dopamine agonists, the unique pocket topology underlying ligand selectivity, the conformational changes in receptor activation, and potential structural determinants for G protein-coupling selectivity. These results provide both a molecular understanding of dopamine signaling and multiple structural templates for drug design targeting the dopaminergic system.

Legend

Protein

Chemical

Disease

Primary Citation of related structures